Supernus [SUPN] vs Lantheus Holdings [LNTH] Detailed Stock Comparison

Supernus Pharmaceuticals Inc.

NASDAQ
Loading...

Lantheus Holdings Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Supernus Pharmaceuticals Inc. wins in 4 metrics, Lantheus Holdings Inc. wins in 16 metrics, with 0 ties. Lantheus Holdings Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Supernus Pharmaceuticals Inc. Lantheus Holdings Inc. Better
P/E Ratio (TTM) 40.66 24.30 Lantheus Holdings Inc.
Price-to-Book Ratio 2.66 4.91 Supernus Pharmaceuticals Inc.
Debt-to-Equity Ratio 3.86 57.19 Supernus Pharmaceuticals Inc.
PEG Ratio -0.33 -0.04 Lantheus Holdings Inc.
EV/EBITDA 22.87 14.70 Lantheus Holdings Inc.
Profit Margin (TTM) -5.36% 15.15% Lantheus Holdings Inc.
Operating Margin (TTM) 5.57% 19.07% Lantheus Holdings Inc.
EBITDA Margin (TTM) 5.57% 19.07% Lantheus Holdings Inc.
Return on Equity -3.68% 21.45% Lantheus Holdings Inc.
Return on Assets (TTM) 1.14% 9.28% Lantheus Holdings Inc.
Free Cash Flow (TTM) $45.99M $348.64M Lantheus Holdings Inc.
1-Year Return 45.68% 31.42% Supernus Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 3.93 3.50 Lantheus Holdings Inc.
Enterprise Value $2.68B $5.62B Lantheus Holdings Inc.
EV/Revenue Ratio 3.73 3.65 Lantheus Holdings Inc.
Gross Profit Margin (TTM) 89.13% 59.21% Supernus Pharmaceuticals Inc.
Revenue per Share (TTM) $13 $23 Lantheus Holdings Inc.
Earnings per Share (Diluted) $-0.68 $3.41 Lantheus Holdings Inc.
Beta (Stock Volatility) 0.73 -0.13 Lantheus Holdings Inc.
Short % of Float 11.09% 10.95% Lantheus Holdings Inc.

Supernus Pharmaceuticals Inc. vs Lantheus Holdings Inc. Stock Performance Analysis

Loading Price Chart...

SUPN
LNTH

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Supernus Pharmaceuticals Inc.-0.06%-7.75%-9.38%-20.00%-0.11%-10.92%
Lantheus Holdings Inc.4.09%-3.76%9.71%26.21%64.47%43.15%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Supernus Pharmaceuticals Inc.45.68%37.73%54.55%136.46%673.53%673.53%
Lantheus Holdings Inc.31.42%11.99%303.82%4,393.21%1,444.32%1,444.32%

Performance & Financial Health Analysis: Supernus Pharmaceuticals Inc. vs Lantheus Holdings Inc.

MetricSUPNLNTH
Market Information
Market Cap i$2.83B$5.39B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i492,694641,334
90 Day Avg. Volume i568,601839,568
Last Close$44.05$100.24
52 Week Range$30.83 - $59.68$47.25 - $103.89
% from 52W High-26.20%-3.51%
All-Time High$61.25 (Jun 25, 2018)$126.89 (Jul 15, 2024)
% from All-Time High-28.08%-21.00%
Growth Metrics
Quarterly Revenue Growth0.22%0.04%
Quarterly Earnings Growth0.21%0.04%
Financial Health
Profit Margin (TTM) i-0.05%0.15%
Operating Margin (TTM) i0.06%0.19%
Return on Equity (TTM) i-0.04%0.21%
Debt to Equity (MRQ) i3.8657.19
Cash & Liquidity
Book Value per Share (MRQ)$18.48$16.87
Cash per Share (MRQ)$5.36$5.56
Operating Cash Flow (TTM) i$47.33M$390.14M
Levered Free Cash Flow (TTM) i$101.29M$265.57M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Supernus Pharmaceuticals Inc. vs Lantheus Holdings Inc.

MetricSUPN (Apr 22, 2026)LNTH (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i40.6624.30
Forward P/E i11.6413.17
PEG Ratio i-0.33-0.04
Price to Sales (TTM) i3.933.50
Price to Book (MRQ) i2.664.91
Market Capitalization
Market Capitalization i$2.83B$5.39B
Enterprise Value i$2.68B$5.62B
Enterprise Value Metrics
Enterprise to Revenue i3.733.65
Enterprise to EBITDA i22.8714.70
Risk & Other Metrics
Beta i0.73-0.13
Book Value per Share (MRQ) i$18.48$16.87

Financial Statements Comparison: Supernus Pharmaceuticals Inc. vs Lantheus Holdings Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSUPN (2025)LNTH (2025)
Revenue/Sales i718.95M1.54B
Cost of Goods Sold i74.56M599.66M
COGS % of Revenue i10.4%38.9%
Gross Profit i644.39M941.95M
Gross Margin i89.6%61.1%
Research & Development i106.24M177.31M
Operating Income (EBIT) i-36.86M315.56M
Operating Margin i-5.1%20.5%
EBITDA i67.95M409.00M
EBITDA Margin i9.5%26.5%
Pre-Tax Income i-49.03M313.79M
Pre-Tax Income % of Revenue i-6.8%20.4%
Income Tax i-10.48M80.23M
Income Tax % of Revenue i-1.5%5.2%
Net Income (Profit) i-38.55M233.56M
Profit Margin i-5.4%15.2%

Balance Sheet & Liquidity Metrics

MetricSUPN (2025)LNTH (2025)
Cash & Equivalents i128.45M359.12M
Total Current Assets i644.18M899.96M
Total Current Assets % of Revenue i89.6%58.4%
Total Current Liabilities i338.17M333.42M
Total Current Liabilities % of Revenue i47.0%21.6%
Long-Term Debt i30.37M618.69M
Long-Term Debt % of Revenue i4.2%40.1%
Total Shareholders Equity i1.06B1.09B
Retained Earnings i517.88M679.50M
Retained Earnings % of Revenue i72.0%44.1%
Property, Plant & Equipment i030.98M

Cash Flow Statement Comparison

MetricSUPN (2025)LNTH (2025)
Operating Cash Flow i67.28M398.13M
Operating Cash Flow % of Revenue i9.4%25.8%
Capital Expenditures i-1.34MN/A
Free Cash Flow i45.99M348.64M
FCF Margin i6.4%22.6%
Debt Repayment i0-1.11M
Common Stock Repurchase iN/A-300.02M

Short Interest & Institutional Ownership Analysis

MetricSUPNLNTH
Shares Short i4.53M5.36M
Short Ratio i7.264.60
Short % of Float i11.09%10.95%
Shares Outstanding i57.46M64.59M
Float Shares i51.79M58.18M
% Held by Insiders i4.34%2.04%
% Held by Institutions i105.00%109.34%
% Held by Public i-9.34%-11.38%

Dividend Analysis & Yield Comparison: Supernus Pharmaceuticals Inc. vs Lantheus Holdings Inc.

MetricSUPNLNTH
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A